<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603445</url>
  </required_header>
  <id_info>
    <org_study_id>CBCL201X2102C</org_study_id>
    <nct_id>NCT02603445</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL</brief_title>
  <official_title>A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib multi-center, open-label study: escalation part followed by expansion
      part. The primary purpose of the Phase Ib CBCL201X2102C study is to characterize the safety
      and tolerability of BCL201 combined with idelalisib in patients with FL and MCL.

      Approximately 65 patients are to be enrolled.

      The primary endpoint for the Phase Ib is frequency, severity and seriousness of AEs, lab
      abnormalities and other safety parameters such as ECG changes. An adaptive Bayesian logistic
      regression model (BLRM) will guide the dose escalation to determine the MTD/RDE in phase Ib.
      In addition Bayesian regression models will be used to estimate the dose-exposure
      relationships for both BCL201 and idelalisib in order to guide the escalation steps. A
      Bayesian method for the expansion part will be used for the primary activity objective.

      The study data will be analyzed and reported based on all patients' data of the escalation
      and expansion part.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Anticipated">June 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Characterized by Frequency, severity and seriousness of AEs, lab abnormalities and other safety parameters such as electrocardiogram (ECG) changes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of dose limiting toxicities (DLTs)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to BCL201 and idelalisib as measured by AUC0-24h at C1D15</measure>
    <time_frame>Cycle = 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BCL201, idelalisib and GS-563117 (metabolite of idelalisib)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in markers such as protein expression ofBcl -2-family members, phospho-AKT, and Ki67</measure>
    <time_frame>For dose escalation: C1D15, C2D1; For dose expansion: C2D1, C2D15 to C3D1</time_frame>
    <description>C = Cycle, D = Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response (PR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (SD)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Follicular Lymphoma (FL)</condition>
  <condition>Mantle Cell Lymphoma (MCL)</condition>
  <arm_group>
    <arm_group_label>Follicular lymphoma (FL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mantle cell lymphoma (MCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCL201</intervention_name>
    <arm_group_label>Follicular lymphoma (FL)</arm_group_label>
    <arm_group_label>Mantle cell lymphoma (MCL)</arm_group_label>
    <other_name>S55746</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <arm_group_label>Follicular lymphoma (FL)</arm_group_label>
    <arm_group_label>Mantle cell lymphoma (MCL)</arm_group_label>
    <other_name>Idela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of FL or MCL according to WHO 2008

          -  Relapsed or refractory with at least one (FL) or two (MCL), but not more than four,
             prior lines of antineoplastic regimens.

          -  Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imaging: &gt;
             1.5 cm for nodal lesion, &gt; 1.0 cm for extra nodal lesion.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

        Exclusion Criteria:

          -  For dose escalation part: Patients with MCL at high risk for tumor lysis syndrome

          -  Prior treatment with PI3Kδ or Bcl-2 inhibitors.

          -  Any other malignant disease

          -  History of serious allergic reactions including anaphylaxis and toxic epidermal
             necrolysis

          -  Inadequate organ function

          -  Concomitant treatment with:

          -  Strong CYP3A4/5 inducers or inhibitors

          -  Sensitive CYP3A4/5 substrates or CYP3A4/5 substrates with narrow therapeutic index
             (NTI)

          -  Sensitive CYP2D6 substrates or CYP2D6 substrates with NTI

          -  Selected dual substrates of CYP3A4/5 and CYP2C8

          -  Selected dual substrates of CYP3A4/5 and CYP2D6

          -  Selected dual substrates of OATP and CYP450

          -  QT prolonging drugs with a known risk to induce TdP

          -  Proton pump inhibitors

          -  Treatment by warfarin or equivalent vitamin K antagonists.

          -  Other investigational therapies

          -  Herbal preparations/ medications

          -  Grapefruit, Seville oranges or products containing either juice

        Other protocol-defined inclusion/exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Dept of IRB</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salma Ahsanuddin</last_name>
      <email>ahsanuds@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Anas Younes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center-University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Addison</last_name>
      <phone>713-792-2828</phone>
      <email>aaaddison@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michael Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Richard Greil</last_name>
      <phone>+43 57255 25800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre-Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>October 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCL201</keyword>
  <keyword>idelalisib</keyword>
  <keyword>Follicular lymphoma</keyword>
  <keyword>FL</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>MCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
